Literature DB >> 10988115

Responses of tracheobronchial receptors to inhaled furosemide in anesthetized rats.

T Sudo1, F Hayashi, T Nishino.   

Abstract

Inhalation of furosemide, a loop diuretic, has shown favorable effects on experimentally induced cough, bronchoconstriction, and dyspnea. The effect of inhaled furosemide on tracheobronchial receptors was studied in anesthetized, spontaneously breathing rats. Single unit or pauci unit activity was recorded from the right vagus nerve. Tracheobronchial receptors were classified into slowly and rapidly adapting receptors (SARs and RARs, respectively), based on their adaptation index (AI), which was derived from the decrease in spike frequency (sf) over 2 s, expressed as a percentage of the peak firing rate. There were 43 SARs (AI </= 25%) and eight RARs (AI >/= 50%). Inhalation of furosemide (n = 29) increased the slope of airway pressure (Paw) versus sf of SARs from 8.6 to 14.8 Hz/cm H(2)O with an increase in sf at Paw = 0 cm H(2)O from 18.0 to 49.5 Hz, resulting in an upward shift of the line. Neither inhalation of vehicle (n = 9) nor intravenous injection of furosemide (n = 5) changed this relationship. In addition, inhalation of furosemide attenuated the activity of RARs. These findings indicate that SARs are sensitized and RARs desensitized by inhalation of furosemide. We discuss possible mechanisms for this, and its relevance to clinical problems of dyspnea, bronchoconstriction, and cough.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10988115     DOI: 10.1164/ajrccm.162.3.2001001

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  13 in total

1.  Aerosol furosemide for dyspnea: High-dose controlled delivery does not improve effectiveness.

Authors:  Robert B Banzett; Richard M Schwartzstein; Robert W Lansing; Carl R O'Donnell
Journal:  Respir Physiol Neurobiol       Date:  2017-08-24       Impact factor: 1.931

2.  Physiological mechanisms of dyspnea during exercise with external thoracic restriction: role of increased neural respiratory drive.

Authors:  Cassandra T Mendonca; Michele R Schaeffer; Patrick Riley; Dennis Jensen
Journal:  J Appl Physiol (1985)       Date:  2013-12-19

3.  Incident diuretic drug use and adverse respiratory events among older adults with chronic obstructive pulmonary disease.

Authors:  Nicholas T Vozoris; Xuesong Wang; Peter C Austin; Denis E O'Donnell; Shawn D Aaron; Teresa M To; Andrea S Gershon
Journal:  Br J Clin Pharmacol       Date:  2017-12-06       Impact factor: 4.335

4.  Aerosol furosemide for dyspnea: Controlled delivery does not improve effectiveness.

Authors:  Capucine Morélot-Panzini; Carl R O'Donnell; Robert W Lansing; Richard M Schwartzstein; Robert B Banzett
Journal:  Respir Physiol Neurobiol       Date:  2017-10-12       Impact factor: 1.931

5.  Controlled Delivery of 80 mg Aerosol Furosemide Does Not Achieve Consistent Dyspnea Relief in Patients.

Authors:  Robert W Hallowell; Richard Schwartzstein; Carl R O'Donnell; Andrew Sheridan; Robert B Banzett
Journal:  Lung       Date:  2019-11-15       Impact factor: 2.584

6.  An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea.

Authors:  Mark B Parshall; Richard M Schwartzstein; Lewis Adams; Robert B Banzett; Harold L Manning; Jean Bourbeau; Peter M Calverley; Audrey G Gift; Andrew Harver; Suzanne C Lareau; Donald A Mahler; Paula M Meek; Denis E O'Donnell
Journal:  Am J Respir Crit Care Med       Date:  2012-02-15       Impact factor: 21.405

Review 7.  The symptomatic relief of dyspnea.

Authors:  Giovanni Elia; Jay Thomas
Journal:  Curr Oncol Rep       Date:  2008-07       Impact factor: 5.075

Review 8.  Pharmacology of airway afferent nerve activity.

Authors:  B J Undem; M J Carr
Journal:  Respir Res       Date:  2001-05-16

9.  Fooling the brain to alleviate dyspnoea.

Authors:  Capucine Morélot-Panzini
Journal:  Eur Respir J       Date:  2017-08-17       Impact factor: 16.671

10.  Effect of Inhaled Nebulized Furosemide (40 and 120 mg) on Breathlessness during Exercise in the Presence of External Thoracic Restriction in Healthy Men.

Authors:  Marcus Waskiw-Ford; Anne Wu; Amar Mainra; Noah Marchand; Abdullatif Alhuzaim; Jean Bourbeau; Benjamin M Smith; Dennis Jensen
Journal:  Front Physiol       Date:  2018-02-12       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.